dutogliptin
Small moleculeexperimental
Clinical trial activity
13 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
13
Phase 3
9
Phase 4
0
Earliest trial started Apr 1, 2006 (NCT00530881)
Timeline
Indications
Mechanism of action
- Dipeptidyl peptidase IVINHIBITOR
DPP4 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O- Mol. weight
- 241.1 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297203 ↗
- ChEMBLCHEMBL4296719 ↗
Also known as
- dutogliptin
- dutogliptin
- dutogliptin
- phx1149
- phx1149
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05881382 | Phase 3 | Sep 30, 2023 | Recardio, Inc. |
| NCT03486080 | Phase 2 | Oct 31, 2018 | Recardio, Inc. |
| NCT01089790 | Phase 3 | Mar 1, 2010 | Forest Laboratories, Phenomix |
| NCT00998686 | Phase 3 | Nov 1, 2009 | Forest Laboratories, Phenomix |
| NCT00958269 | Phase 3 | Aug 1, 2009 | Forest Laboratories, Phenomix |
| NCT00970424 | Phase 3 | Aug 1, 2009 | Forest Laboratories, Phenomix |
| NCT00947557 | Phase 3 | Jul 1, 2009 | Forest Laboratories, Phenomix |
| NCT00850239 | Phase 3 | May 1, 2009 | Forest Laboratories, Phenomix |
| NCT00865592 | Phase 3 | Mar 1, 2009 | Forest Laboratories, Phenomix |
| NCT00690638 | Phase 3 | Jul 1, 2008 | Forest Laboratories, Phenomix |
| NCT01101945 | Phase 2 | Jul 1, 2007 | Phenomix |
| NCT00482950 | Phase 2 | Apr 1, 2007 | Phenomix |
| NCT00530881 | Phase 2 | Apr 1, 2006 | Phenomix |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Phenomix | For profit | 11 | 8 | 2 | 2006 |
| Forest Laboratories | For profit | 8 | 3 | 1 | 2008 |
| Recardio, Inc. | For profit | 2 | 2 | 2 | 2018 |
3 organizations
Page 1 / 1